Abstract Prostate cancer (PCa) is the 2nd most common cancer in men worldwide, excluding non-melanoma skin cancers. Whilst androgen deprivation therapy initially proves effective, the inevitable development of castration-resistance renders the disease incurable. Therefore, novel therapeutic approaches are urgently needed to improve treatment options and outcomes for patients with aggressive PCa. Our lab has previously shown that cannabidiol (CBD), a major non-psychoactive cannabinoid, reduces PCa cell viability and alters expression of key cell cycle proteins in in vitro cell line models and induced apoptosis in non-cancerous PCa cells. However, a knowledge gap surrounds the mechanism of entry of CBD into PCa cells. The aim of this study was to bring CBD forward into physiologically relevant 3D ex vivo PCa tissue models as well as explore how CBD is getting into PCa cells. Surgical biopsies were obtained from patients undergoing radical prostatectomy. Tumour cores were precision-cut to generate 200µm-thick tissue slice cultures (TSCs), incubated for 24hr, 0. 001, consistent with our previous findings in PCa cell lines. In terms of receptor expression, CNR1, CNR2, GPR55, 2026 Jan 20-22; Philadelphia PA. Philadelphia (PA): AACR; Cancer Res 2026;86 (2Suppl): Abstract nr B044.
Magee et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: